Edward Tuddenham

List of Publications by Citations

224 papers	15,253 citations	60 h-index	120 g-index
239 ext. papers	16,482 ext. citations	9.3 avg, IF	5.78 L-index

#	Paper	IF	Citations
224	Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. *New England Journal of Medicine*, **2011**, 365, 2357-65	59.2	1271
223	Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. *Nature*, **2004**, 427, 537-41	50.4	905
222	Long-term safety and efficacy of factor IX gene therapy in hemophilia B. *New England Journal of Medicine*, **2014**, 371, 1994-2004	59.2	810
221	Structure of human factor VIII. *Nature*, **1984**, 312, 337-42	50.4	788
220	The hemophilias--from royal genes to gene therapy. *New England Journal of Medicine*, **2001**, 344, 1773-9	59.2	747
219	Expression of active human factor VIII from recombinant DNA clones. *Nature*, **1984**, 312, 330-7	50.4	621
218	Biopsy of human preimplantation embryos and sexing by DNA amplification. *Lancet, The*, **1989**, 1, 347-9	40	353
217	Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. *Blood*, **2006**, 107, 2653-61	2.2	323
216	Distribution of factor VIII mRNA and antigen in human liver and other tissues. *Nature*, **1985**, 317, 726-9	50.4	252
215	Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. *Nature Genetics*, **2003**, 34, 220-5	36.3	243
214	Genetic mapping and diagnosis of haemophilia A achieved through a BclI polymorphism in the factor VIII gene. *Nature*, **1985**, 314, 738-40	50.4	228
213	Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation. *Thrombosis and Haemostasis*, **1995**, 74, 1402-1406	7	228
212	Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. *Blood*, **2007**, 109, 1414-21	2.2	219
211	Crystal structure of the extracellular region of human tissue factor. *Nature*, **1994**, 370, 662-6	50.4	205
210	Noninvasive prenatal diagnosis of hemophilia by microfluidics digital PCR analysis of maternal plasma DNA. *Blood*, **2011**, 117, 3684-91	2.2	199
209	A Molecular Model for the Triplicated A Domains of Human Factor VIII Based on the Crystal Structure of Human Ceruloplasmin. *Blood*, **1997**, 89, 2413-2421	2.2	198
208	Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. *Blood*, **2013**, 121, 3335-44	2.2	186

207	A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. *Nature Genetics*, **1994**, 6, 205-9	36.3	174
206	Detection and sequence of mutations in the factor VIII gene of haemophiliacs. *Nature*, **1985**, 315, 427-30	50.4	174
205	The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. *Nucleic Acids Research*, **1998**, 26, 216-9	20.1	170
204	Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand disease. *British Journal of Haematology*, **1982**, 52, 259-67	4.5	154
203	High Prevalence of Elevated Factor VIII Levels in Patients Referred for Thrombophilia Screening: Role of Increased Synthesis and Relationship to the Acute Phase Reaction. *Thrombosis and Haemostasis*, **1997**, 77, 0825-0828	7	152
202	Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1994-2000	15.4	145
201	Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. *American Heart Journal*, **1994**, 127, 607-12	4.9	135
200	Codon optimization of human factor VIII cDNAs leads to high-level expression. *Blood*, **2011**, 117, 798-807	2.2	133
199	Factor VII deficiency and the FVII mutation database. *Human Mutation*, **2001**, 17, 3-17	4.7	132
198	A new polymorphism in the factor VIII gene for prenatal diagnosis of hemophilia A. *Nucleic Acids Research*, **1986**, 14, 4535-42	20.1	130
197	HLA Genotype of Patients with Severe Haemophilia A due to Intron 22 Inversion with and without Inhibitors of Factor VIII. *Thrombosis and Haemostasis*, **1997**, 77, 238-242	7	129
196	450 million years of hemostasis. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 1487-94	15.4	126
195	Environmental and genetic factors influencing inhibitor development. *Seminars in Hematology*, **2004**, 41, 82-8	4	126
194	Characterization of a murine homeo box gene, Hox-2.6, related to the Drosophila Deformed gene. *Genes and Development*, **1988**, 2, 1424-38	12.6	126
193	Haemophilia A diagnosis by analysis of a hypervariable dinucleotide repeat within the factor VIII gene. *Lancet, The*, **1991**, 338, 207-11	40	124
192	Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. *Blood*, **2008**, 112, 919-21	2.2	119
191	Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies. *Biochemistry*, **1985**, 24, 4294-300	3.2	119
190	Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. *Blood*, **2004**, 104, 2714-21	2.2	114

189	Molecular etiology of factor VIII deficiency in hemophilia A. *Human Mutation*, **1995**, 5, 1-22	4.7	110
188	Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene. *Nucleic Acids Research*, **1991**, 19, 4821-33	20.1	108
187	Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. *Thrombosis and Haemostasis*, **2005**, 93, 23-6	7	104
186	An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 1329-40	15.4	98
185	Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. *Blood*, **1984**, 63, 31-41	2.2	96
184	A clinically useful DNA probe closely linked to haemophilia A. *Lancet, The*, **1984**, 2, 6-8	40	94
183	Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. *Blood*, **2006**, 107, 1903-7	2.2	90
182	A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome. *Blood*, **2005**, 106, 542-9	2.2	87
181	Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. *American Journal of Transplantation*, **2004**, 4, 1958-63	8.7	82
180	Desmopressin and bleeding time in patients with cirrhosis. *British Medical Journal*, **1985**, 291, 1377-81		82
179	Molecular analysis of the genotype-phenotype relationship in factor VII deficiency. *Human Genetics*, **2000**, 107, 327-42	6.3	79
178	Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. *Nucleic Acids Research*, **1994**, 22, 3511-33	20.1	79
177	Molecular evolution of the vertebrate blood coagulation network. *Thrombosis and Haemostasis*, **2003**, 89, 420-428	7	78
176	Crystal structure of active site-inhibited human coagulation factor VIIa (des-Gla). *Journal of Structural Biology*, **1999**, 127, 213-23	3.4	73
175	Menorrhagia in adolescents with inherited bleeding disorders. *Journal of Pediatric and Adolescent Gynecology*, **2010**, 23, 215-22	2	72
174	Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. *British Journal of Haematology*, **1998**, 100, 773-6	4.5	70
173	Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. *Haemophilia*, **2009**, 15, 501-8	3.3	68
172	Inherited Factor VII Deficiency: Molecular Genetics and Pathophysiology. *Thrombosis and Haemostasis*, **1997**, 78, 151-160	7	68

171	Inherited Factor X Deficiency: Molecular Genetics and Pathophysiology. *Thrombosis and Haemostasis*, **1997**, 78, 161-172	7	68
170	Haemophilia A diagnosis by simultaneous analysis of two variable dinucleotide tandem repeats within the factor VIII gene. *British Journal of Haematology*, **1994**, 86, 804-9	4.5	66
169	Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). *Biochemistry*, **1994**, 33, 14162-9	3.2	66
168	Von Willebrand factor multimer patterns in von Willebrand's disease. *British Journal of Haematology*, **1983**, 55, 493-507	4.5	66
167	Thromboelastography, whole-blood haemostasis and recurrent miscarriage. *Human Reproduction*, **2003**, 18, 2540-3	5.7	63
166	A G-->A substitution in an HNF I binding site in the human alpha-fetoprotein gene is associated with hereditary persistence of alpha-fetoprotein (HPAFP). *Human Molecular Genetics*, **1993**, 2, 379-84	5.6	62
165	Haemostatic problems in liver disease. *Gut*, **1986**, 27, 339-49	19.2	60
164	Synthesis and release of factor VIII by cultured human endothelial cells. *British Journal of Haematology*, **1981**, 47, 617-26	4.5	57
163	Bernard Soulier syndrome in pregnancy: a systematic review. *Haemophilia*, **2010**, 16, 584-91	3.3	55
162	Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs. *British Journal of Haematology*, **1995**, 91, 458-64	4.5	55
161	Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. *Blood*, **1996**, 87, 4187-4196	2.2	54
160	Localization of factor VIIIC: antigen in guinea-pig tissues and isolated liver cell fractions. *British Journal of Haematology*, **1984**, 56, 535-43	4.5	54
159	Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII. *British Journal of Haematology*, **1994**, 86, 610-8	4.5	51
158	Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. *Blood*, **2008**, 111, 5592-600	2.2	50
157	Coagulation and fibrosis in chronic liver disease. *Gut*, **2008**, 57, 1722-7	19.2	47
156	Inactivation of factor VIII by factor IXa. *Biochemistry*, **1992**, 31, 2805-12	3.2	47
155	Factor Xa and thrombin, but not factor VIIa, elicit specific cellular responses in dermal fibroblasts. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 1935-44	15.4	46
154	Homozygous protein C deficiency with delayed onset of symptoms at 7 to 10 months. *Thrombosis Research*, **1989**, 53, 475-84	8.2	46

153	Six point mutations that cause factor XI deficiency. *Blood*, **1995**, 85, 1509-1516	2.2	46
152	Science, medicine, and the future: assessing thrombotic risk. *BMJ: British Medical Journal*, **1998**, 317, 520-3		45
151	Coronary Thrombosis and the Platelet Glycoprotein IIIA Gene PLA2 Polymorphism. *Thrombosis and Haemostasis*, **1998**, 80, 218-219	7	45
150	Prospects for gene therapy of haemophilia. *Haemophilia*, **2004**, 10, 309-18	3.3	44
149	Advances in Gene Therapy for Hemophilia. *Human Gene Therapy*, **2017**, 28, 1004-1012	4.8	43
148	The Factor VIII Mutation Database on the World Wide Web: the haemophilia A mutation, search, test and resource site. HAMSTeRS update (version 3.0). *Nucleic Acids Research*, **1997**, 25, 128-32	20.1	43
147	Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein. *Human Genetics*, **1997**, 101, 323-32	6.3	43
146	Epidemiology of coagulation disorders. *Best Practice and Research: Clinical Haematology*, **1992**, 5, 383-439		42
145	Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium. *Blood*, **2004**, 104, 1344-9	2.2	41
144	Energetic contributions and topographical organization of ligand binding residues of tissue factor. *Biochemistry*, **1995**, 34, 6310-5	3.2	41
143	Factor VIII - novel insights into form and function. *British Journal of Haematology*, **2002**, 119, 323-31	4.5	40
142	Regulated inhibition of coagulation by porcine endothelial cells expressing P-selectin-tagged hirudin and tissue factor pathway inhibitor fusion proteins. *Transplantation*, **1999**, 68, 832-9	1.8	39
141	A maximum likelihood estimate of the sex ratio of mutation rates in haemophilia A. *Human Genetics* , **1983**, 64, 156-9	6.3	38
140	AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. *Blood*, **2012**, 119, 957-66	2.2	37
139	The locus for combined factor V-factor VIII deficiency (F5F8D) maps to 18q21, between D18S849 and D18S1103. *American Journal of Human Genetics*, **1997**, 61, 143-50	11	37
138	Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. *Thrombosis and Haemostasis*, **2011**, 106, 521-7	7	36
137	Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. *Blood*, **2004**, 103, 3381-7	2.2	36
136	Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer. *Blood*, **2018**, 132, 491-491	2.2	36

135	Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C. *British Journal of Haematology*, **2003**, 123, 496-501	4.5	35
134	Identification of two novel mutations in non-Jewish factor XI deficiency. *British Journal of Haematology*, **1995**, 90, 916-20	4.5	35
133	Immunologic studies of factor VIII coagulant activity (VIII:C) 1. Assays based on a haemophilic and an acquired antibody to VIII:C. *Thrombosis Research*, **1981**, 21, 431-45	8.2	33
132	An immunoradiometric assay for human factor VIII/von Willebrand factor (VIII:vWF) using a monoclonal antibody that defines a functional epitope. *British Journal of Haematology*, **1985**, 59, 565-77	4.5	32
131	Solution structure of the major factor VIII binding region on von Willebrand factor. *Blood*, **2014**, 123, 4143-51	2.2	31
130	Live birth following the first mutation specific pre-implantation genetic diagnosis for haemophilia A. *Thrombosis and Haemostasis*, **2006**, 95, 373-9	7	31
129	Efficient gene transfer into human umbilical vein endothelial cells allows functional analysis of the human tissue factor gene promoter. *British Journal of Haematology*, **1994**, 88, 122-8	4.5	31
128	Inhibition of tissue factor-dependent and -independent coagulation by cell surface expression of novel anticoagulant fusion proteins. *Transplantation*, **1999**, 67, 467-74	1.8	31
127	The genetic basis of inhibitor development in haemophilia A. *Haemophilia*, **1998**, 4, 543-5	3.3	30
126	von Willebrand factor and its disorders: an overview of recent molecular studies. *Blood Reviews*, **1989**, 3, 251-62	11.1	30
125	Antenatal diagnosis and carrier detection of haemophilia A using factor VIII gene probe. *Lancet, The* , **1985**, 1, 1093-4	40	30
124	Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq) in adults with severe haemophilia A: efficacy and safety. *Haemophilia*, **2016**, 22, 225-231	3.3	30
123	Expression of hirudin fusion proteins in mammalian cells: a strategy for prevention of intravascular thrombosis. *Circulation*, **1998**, 98, 2744-52	16.7	29
122	Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe hemophilia A. *Blood*, **1989**, 73, 2117-2122	2.2	29
121	Platelet membrane glycoprotein Ibalpha gene -5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis. *British Heart Journal*, **2002**, 87, 70-4		28
120	Severe perinatal thrombosis in double and triple heterozygous offspring of a family segregating two independent protein S mutations and a protein C mutation. *Blood*, **1996**, 87, 3731-3737	2.2	28
119	Synthesis and characterization of wild-type and variant gamma-carboxyglutamic acid-containing domains of factor VII. *Biochemistry*, **1993**, 32, 13949-55	3.2	28
118	High-level production of human blood coagulation factors VII and XI using a new mammalian expression vector. *Gene*, **1994**, 139, 275-9	3.8	28

117	High Purity Factor IX and Prothrombin Complex Concentrate (PCC): Pharmacokinetics and Evidence that Factor IXa Is the Thrombogenic Trigger in PCC. *Thrombosis and Haemostasis*, **1996**, 76, 023-028	7	28
116	Detection of missense mutations by single-strand conformational polymorphism (SSCP) analysis in five dysfunctional variants of coagulation factor VII. *Human Molecular Genetics*, **1993**, 2, 1355-9	5.6	26
115	The effect of liver disease on factors V, VIII and protein C. *British Journal of Haematology*, **1985**, 61, 541-8	4.5	26
114	Changes in the levels of factor VIII and von Willebrand factor in the puerperium. *Haemophilia*, **2012**, 18, 241-5	3.3	25
113	Structural analysis of eight novel and 112 previously reported missense mutations in the interactive FXI mutation database reveals new insight on FXI deficiency. *Thrombosis and Haemostasis*, **2009**, 102, 287-301	7	25
112	Thrombin generation assay identifies individual variability in responses to low molecular weight heparin in pregnancy: implications for anticoagulant monitoring. *British Journal of Haematology*, **2015**, 168, 719-27	4.5	24
111	The impact of sport on health status, psychological well-being and physical performance of adults with haemophilia. *Haemophilia*, **2016**, 22, 521-30	3.3	24
110	Optimizing warfarin reversal--an ex vivo study. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 1123-7	15.4	24
109	Analysis of the essential sequences of the factor VIII gene in twelve haemophilia A patients by single-stranded conformation polymorphism. *Blood Coagulation and Fibrinolysis*, **1994**, 5, 257-64	1	24
108	Factor VIII Ise (R2159C) in a Patient with Mild Hemophilia A, an Abnormal Factor VIII with Retention of Function but Modification of C2 Epitopes. *Thrombosis and Haemostasis*, **1997**, 77, 0862-0867	7	24
107	Gene Therapy for Hemophilia. *Hematology/Oncology Clinics of North America*, **2017**, 31, 853-868	3.1	23
106	Mutations in haemophilia A. *British Journal of Haematology*, **1993**, 83, 450-8	4.5	23
105	The haemophilia A mutation search test and resource site, home page of the factor VIII mutation database: HAMSTeRS. *Nucleic Acids Research*, **1996**, 24, 100-2	20.1	22
104	Hyperviscosity syndrome in IgA multiple myeloma. *British Journal of Haematology*, **1974**, 27, 65-76	4.5	22
103	Recent advances in developing specific therapies for haemophilia. *British Journal of Haematology*, **2018**, 181, 161-172	4.5	21
102	A molecular model of the serine protease domain of activated protein C: application to the study of missense mutations causing protein C deficiency. *British Journal of Haematology*, **1993**, 84, 290-300	4.5	21
101	Albinism with haemorrhagic diathesis: Hermansky-Pudlak syndrome. *British Journal of Ophthalmology*, **1985**, 69, 904-8	5.5	21
100	A common ancestral glycoprotein (GP) 9 1828A>G (Asn45Ser) gene mutation occurring in European families from Australia and Northern Europe with Bernard-Soulier Syndrome (BSS). *Thrombosis and Haemostasis*, **2005**, 94, 599-605	7	20

99	Alpha1-antitrypsin Pittsburgh in a family with bleeding tendency. *Haematologica*, **2009**, 94, 881-4	6.6	19
98	Human Tissue Factor Pathway Inhibitor Fused to CD4 Binds both FXa and TF/FVIIa at the Cell Surface. *Thrombosis and Haemostasis*, **1997**, 78, 1488-1494	7	19
97	The varieties of von Willebrand disease. *International Journal of Laboratory Hematology*, **1984**, 6, 307-23		18
96	CRM+ haemophilia A due to a missense mutation (372----Cys) at the internal heavy chain thrombin cleavage site. *British Journal of Haematology*, **1990**, 75, 73-7	4.5	18
95	GO-8: Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant. *Blood*, **2018**, 132, 489-489	2.2	18
94	Postinjury vascular intimal hyperplasia in mice is completely inhibited by CD34+ bone marrow-derived progenitor cells expressing membrane-tethered anticoagulant fusion proteins. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2191-8	15.4	17
93	Coagulation factor VII Gln100 --> Arg. Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function. *Journal of Biological Chemistry*, **1998**, 273, 8516-21	5.4	17
92	Thrombophilia: a new factor emerges from the mists. *Lancet, The*, **1993**, 342, 1501-2	40	17
91	Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno-Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B. *Blood*, **2010**, 116, 248-248	2.2	17
90	Studies on immunological assay of vitamin K dependent factors. II. Comparison of four immunoassay methods with functional activity of protein C in human plasma. *British Journal of Haematology*, **1986**, 62, 183-93	4.5	16
89	Analysis of the consequences of premature termination codons within factor VIII coding sequences. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 139-46	15.4	15
88	Symptomatic type II protein C deficiency caused by a missense mutation (Gly 381-->Ser) in the substrate-binding pocket. *British Journal of Haematology*, **1993**, 84, 285-9	4.5	15
87	Gene therapy for haemophilia B. *Haemophilia*, **2012**, 18 Suppl 4, 13-7	3.3	14
86	Endogenous heparinoids contribute to coagulopathy in patients with liver disease. *Journal of Hepatology*, **2008**, 48, 371-2; author reply 372-3	13.4	14
85	Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins. *Xenotransplantation*, **2001**, 8, 258-65	2.8	14
84	Factor VIIa and the extracellular domains of human tissue factor form a compact complex: a study by X-ray and neutron solution scattering. *FEBS Letters*, **1995**, 374, 141-6	3.8	14
83	Use of a non-depleting anti-CD4 antibody to modulate the immune response to coagulation factors VIII and IX. *British Journal of Haematology*, **2002**, 118, 839-42	4.5	13
82	Structural requirements for the interaction between tissue factor and factor VII: characterization of chymotrypsin-derived tissue factor polypeptides. *Biochemical Journal*, **1993**, 292 (Pt 1), 7-12	3.8	12

81	Thrombophilia: the new factor is old factor V. *Lancet, The*, **1994**, 343, 1515-6	40	12
80	Haemophilia A: carrier detection and prenatal diagnosis by linkage analysis using DNA polymorphism. *Journal of Clinical Pathology*, **1987**, 40, 971-7	3.9	12
79	Tissue localization and synthesis of factor-VIII-related antigen in the human foetus. *British Journal of Haematology*, **1974**, 26, 669-77	4.5	11
78	An Alloantibody Recognizing the FVIII A1 Domain in a Patient with CRM Reduced Haemophilia A due to Deletion of a Large Portion of the A1 Domain DNA Sequence. *Thrombosis and Haemostasis*, **2000**, 84, 442-448	7	10
77	Increase of activated factor VIIA and haemostatic molecular markers in juvenile chronic arthritis. *Rheumatology*, **1995**, 34, 466-9	3.9	10
76	Reactions to low-molecular-weight porcine factor VIII concentrates. *British Medical Journal*, **1981**, 283, 381-2		10
75	Factor VIII gene analysis in Japanese CRM-positive and CRM-reduced haemophilia A patients by single-strand conformation polymorphism. *British Journal of Haematology*, **1997**, 98, 901-6	4.5	9
74	Characterisation of blood coagulation factor XI T475I. *Thrombosis and Haemostasis*, **2005**, 93, 1082-8	7	9
73	Crystallization and preliminary X-ray analysis of human tissue factor extracellular domain. *Journal of Molecular Biology*, **1993**, 234, 1263-5	6.5	9
72	Production of factor VIII deficient plasma by immunodepletion using three monoclonal antibodies. *British Journal of Haematology*, **1987**, 66, 497-502	4.5	9
71	A Single Intravenous Infusion of FLT180a Results in Factor IX Activity Levels of More Than 40% and Has the Potential to Provide a Functional Cure for Patients with Haemophilia B. *Blood*, **2018**, 132, 631-631	2.2	9
70	The Interaction of Botrocetin with Normal or Variant von Willebrand Factor (Types IIA and IIB) and Its Inhibition by Monoclonal Antibodies that Block Receptor Binding. *Thrombosis and Haemostasis*, **1992**, 68, 464-469	7	9
69	Global coagulation assays in hemophilia A: A comparison to conventional assays. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 298-308	5.1	8
68	Characterisation of lymphocyte responses to Ca2+ in Scott syndrome. *Thrombosis and Haemostasis*, **2004**, 91, 412-415	7	8
67	Identification of factor IX mutations in Iranian haemophilia B patients by SSCP and sequencing. *Thrombosis Research*, **2007**, 120, 135-9	8.2	7
66	Two novel mutations in severe factor VII deficiency. *British Journal of Haematology*, **2004**, 126, 105-10	4.5	7
65	Identification of six functional clotting factor VIII:C epitopes by analysis of cross-reactive public idiotypes in murine monoclonal VIII:C inhibitors. *Thrombosis Research*, **1987**, 45, 527-37	8.2	7
64	Monoclonal antibodies to human factor VII: a one step immunoradiometric assay for VII:Ag. *Journal of Clinical Pathology*, **1988**, 41, 337-41	3.9	7

63	Morphological and functional disturbances of platelets induced by cryopreservation. *Journal of Clinical Pathology*, **1982**, 35, 870-4	3.9	7
62	Purification and characterization of factor VII 304-Gln: a variant molecule with reduced activity isolated from a clinically unaffected male. *Blood*, **1991**, 78, 132-140	2.2	7
61	Disappearance of Antibodies to Factor VIII in a Patient with Acquired Haemophilia and Carcinoma of the Pancreas During Cytotoxic Therapy with Fluorouracil and CCNU. *Thrombosis and Haemostasis*, **1984**, 52, 131-133	7	7
60	Human congenital diseases with mixed modes of inheritance have a shortage of recessive disease. A demographic scenario?. *Annals of Human Genetics*, **2011**, 75, 688-93	2.2	6
59	Detection of functional differences between different platelet membrane glycoprotein Ibalpha variable number tandem repeat and Kozak genotypes as shown by the PFA-100 system. *Heart*, **2006** , 92, 676-8	5.1	6
58	In search of the eighth factor: a personal reminiscence. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 403-9	15.4	6
57	Gene therapy for hemophilia? Gene therapy for hemophilia is both desirable and achievable in the near future. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 1314	15.4	6
56	Gene therapy for the haemophilias. *Haemophilia*, **2000**, 6 Suppl 1, 115-9	3.3	6
55	Crystallization and preliminary X-ray analysis of active site-inhibited human coagulation factor VIIa (des-Gla). *Journal of Structural Biology*, **1999**, 125, 90-3	3.4	6
54	Studies on immunological assay of vitamin K dependent factors. I. Measurement of factor VII antigen by radioimmunoassay. *British Journal of Haematology*, **1986**, 62, 171-81	4.5	6
53	Letter: Endothelial cells and factor VIII-related protein. *Lancet, The*, **1976**, 1, 46	40	6
52	Genetics of haemostasis. *Haemophilia*, **2012**, 18 Suppl 4, 73-80	3.3	5
51	Therapeutic shoulder arthroscopy in patients with clotting disorders. *Haemophilia*, **2008**, 14, 859-61	3.3	5
50	A Standard Nomenclature for Factor VIII and Factor IX Gene Mutations and Associated Amino Acid Alterations. *Thrombosis and Haemostasis*, **1994**, 72, 475-476	7	5
49	Flip tip inversion and haemophilia A. *Lancet, The*, **1994**, 343, 307-8	40	5
48	Axillary vein thrombosis in adolescent onset systemic sclerosis. *Annals of the Rheumatic Diseases*, **1990**, 49, 557-9	2.4	5
47	The effect of an acute phase reaction and BCG innoculation on factor VIII in the guinea-pig. *Thrombosis Research*, **1985**, 40, 445-51	8.2	5
46	Detachment of endothelial cells by polymorphonuclear leukocytes in vitro: potentiation by antibody coating and prevention by inflammatory exudate. *Journal of Periodontology*, **1981**, 52, 668-72	4.6	5

45	Molecular biological aspects of inhibitor development. *Vox Sanguinis*, **1999**, 77 Suppl 1, 13-6	3.1	5
44	First steps in the standardization of immunoglobulin IgG myeloperoxidase-anti-neutrophil cytoplasmic antibody measurements. *Clinical and Experimental Immunology*, **2016**, 183, 193-205	6.2	5
43	Interaction Between the a3 Region of Factor VIII and the TIL'E'N Domains of the von Willebrand Factor. *Biophysical Journal*, **2019**, 117, 479-489	2.9	4
42	In search of the source of factor VIII. *Blood*, **2014**, 123, 3691	2.2	4
41	Anticoagulation after liver transplantation: a retrospective audit and case-control study. *Blood Coagulation and Fibrinolysis*, **2009**, 20, 615-8	1	4
40	17 Levonorgestrel-releasing intrauterine system for the management of menorrhagia in women with inherited bleeding disorders: Long term follow-up. *Thrombosis Research*, **2007**, 119, S101	8.2	4
39	Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM(-)) and G1948D (CRM(r)). *British Journal of Haematology*, **2001**, 113, 604-15	4.5	4
38	Myeloproliferative and metabolic causes. *Best Practice and Research: Clinical Haematology*, **1994**, 7, 591-635		4
37	Factor VIIShinjo: a dysfunctional factor VII variant homozygous for the substitution Gln for Arg at position 79. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **1995**, 25, 89-97		4
36	Response to desmopressin in type IID von Willebrand'N disease. *International Journal of Laboratory Hematology*, **1989**, 11, 189-97		4
35	Characterization of a Panel of Monoclonal Antibodies to Human Coagulation Factor XI and Detection of Factor XI in Hep G2 Cell Conditioned Medium. *Thrombosis and Haemostasis*, **1990**, 63, 417-423	7	4
34	Factor VIII: the protein, cloning its gene, synthetic factor and now - 35 years later - gene therapy; what happened in between?. *British Journal of Haematology*, **2020**, 189, 400-407	4.5	4
33	Factor VIII: purer is not necessarily better. *Blood*, **2006**, 107, 4-5	2.2	3
32	Molecular genetics of familial venous thrombosis. *British Medical Bulletin*, **1994**, 50, 833-50	5.4	3
31	A monoclonal antibody based immunoradiometric assay for von Willebrand factor: survey of a large patient group. *Thrombosis Research*, **1987**, 45, 101-8	8.2	3
30	Monoclonal antibodies to human factor VII: production of immunodepleted plasma for VII:C assays. *Journal of Clinical Pathology*, **1988**, 41, 342-5	3.9	3
29	Inherited bleeding disorders. *International Anesthesiology Clinics*, **1985**, 23, 61-72	0.6	3
28	Immunologic studies of factor VIII coagulant activity (VIII:C). 2. Factor VIII in selected vertebrates. *Thrombosis Research*, **1982**, 25, 423-31	8.2	3

27	Platelets are a safe way to deliver factor VIII. After 13 years of preclinical research it is now time for a clinical trial. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 96-97	15.4	2
26	Genetic aspects and research development in haemostasis. *Haemophilia*, **2008**, 14 Suppl 3, 113-8	3.3	2
25	Genetic and Laboratory Diagnosis90-98		2
24	Lipogranuloma of the breast due to phenothiazine therapy. *British Journal of Surgery*, **1970**, 57, 76-9	5.3	2
23	O-132. Computerized thromboelastographic parameters amongst women with recurrent miscarriage□vidence for a pro-thrombotic state. *Human Reproduction*, **1999**, 14, 73-73	5.7	2
22	Cloned factor VIII and the molecular genetics of hemophilia. *Cold Spring Harbor Symposia on Quantitative Biology*, **1986**, 51 Pt 1, 365-9	3.9	2
21	Double heterozygosity for mutations in the platelet glycoprotein IX gene in three siblings with Bernard-Soulier syndrome. *Blood*, **1993**, 81, 2339-2347	2.2	2
20	Detection and characterization of seven novel protein S (PROS) gene lesions: evaluation of reverse transcript-polymerase chain reaction as a mutation screening strategy. *Blood*, **1995**, 86, 2632-2641	2.2	2
19	Far away and long ago. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 34-5	15.4	1
18	Journal rubric. Haemophilic pseudotumour of the carotid artery. *Vascular Medicine*, **2012**, 17, 193-4	3.3	1
17	Consideration of platelet function disorders in patients with reduced VWF levels. *Haemophilia*, **2008**, 14, 1131-2	3.3	1
16	Killing 2 birds with 1 stone. *Blood*, **2008**, 112, 2595	2.2	1
15	Regulated endothelial cell expression of novel anticoagulants: a strategy for the prevention and therapy of intravascular thrombosis. *Transplantation Proceedings*, **2000**, 32, 971	1.1	1
14	The tissue factor-factor VII complex: recent advances towards elucidating the structure and function of the initiator of haemostasis. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **1996**, 26 Suppl 1, 20-4		1
13	Studies on immunological assay of vitamin-K dependent factors. III. A double monoclonal immunoradiometric assay for factor IX antigen. *British Journal of Haematology*, **1986**, 62, 513-24	4.5	1
12	Assessing the Potential of Perinatal Gene Transfer Using Congenital Factor VII Deficiency as a Model System. *Blood*, **2010**, 116, 247-247	2.2	1
11	Stable High Level Coagulation Factor VIII Expression In Vivo Following Gene Transfer Using a Novel Expression Cassette Encoding a More Potent FVIII Variant. *Blood*, **2010**, 116, 250-250	2.2	1
10	Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgical Procedures - Results From the guardian□Trials.. *Blood*, **2012**, 120, 2228-2228	2.2	1

9	Stable Factor IX Activity Following AAV-Mediated Gene Transfer in Patients with Severe Hemophilia B. *Blood*, **2012**, 120, 752-752	2.2	1
8	Normal Haemostasis783-807		1
7	Commentary on book review: A History of Blood Coagulation. *Haemophilia*, **2002**, 8, 62-62	3.3	
6	Methylenetetrahydrofolate reductase mutation and coronary artery disease. *Circulation*, **1998**, 98, 2932-2	16.7	
5	Haemophilia: does the future lie in replacement therapy or auto-supply?. *Journal of the Royal Society of Medicine*, **1998**, 91, 506	2.3	
4	Exclusion of the First EGF Domain of Factor VII by a Splice Site Mutation Causes Lethal Factor VII Deficiency. *Blood*, **1998**, 92, 920-926	2.2	
3	Cellular Immune Responses To Vector In a Gene Therapy Trial For Hemophilia B Using An AAV8 Self-Complementary Factor IX Vector. *Blood*, **2013**, 122, 717-717	2.2	
2	Mutations of factor VIII cleavage sites in hemophilia A. *Blood*, **1988**, 72, 1022-1028	2.2	
1	Haemophilia A and Haemophilia B1-92		